logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Baloxavir marboxil for the post-exposure prevention of influenza in people aged 12 years and older

< Back

Baloxavir marboxil for the post-exposure prevention of influenza in people aged 12 years and older

Drugs

Infectious Disease and Immunisation

March 2020


Baloxavir marboxil is a medicinal product currently in development for the post-exposure prophylaxis (prevention) of influenza in individuals aged 12 years and above. Influenza or ‘flu’ is a common virus infection which causes high temperature, body aches, tiredness, cough, sore throat, headache, diarrhoea and nausea. Flu is usually spread by coughs and sneezes and occurs in annual flu seasons (commonly October to May). Most cases of flu will resolve within three to seven days. Although vaccines are the preferred method of flu prevention, they require continual evolution and may not provide protection to everyone. Other treatments are therefore also recommended for flu prevention and containment.

Baloxavir marboxil is given by mouth as tablets and works in a different way to existing flu medications by blocking a specific process which influenza viruses use to multiply within the body. There is evidence that this medication may be effective in people for whom existing flu medicines do not work. Additionally, only one dose of baloxavir marboxil is needed whereas existing flu prevention medications need to be taken over several days. If licenced, baloxavir marboxil may offer an additional prevention option for individuals who have been in contact with someone who has influenza.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts